#United States #Boston #Immuno-Oncology #IO360º #Summit 2026

Unveiling the Future of Cancer Treatment: The Immuno-Oncology 360º Summit 2026

Introduction

The Immuno-Oncology 360º Summit (IO360º) is returning for its 12th annual event, set to take place from February 10-12, 2026, at the Sheraton Boston Hotel, Massachusetts. This vital gathering focuses on the latest advancements in immunotherapy and its application in cancer treatment. At this year's summit, various pharmaceutical and biotech companies will join forces to discuss the critical capabilities needed to enhance the drug development pipeline.

Key Highlights

IO360º is dedicated to uniting various stakeholders from the science and business sectors to explore significant data impacting immuno-oncology. As stated by Kate Woda, Senior Director of IO360º, the event carefully selects solution providers who are not only leaders in their fields but also contribute significantly to the infrastructure and innovation that fuels drug development.

The summit will feature an impressive lineup of sponsors,
including:

• - 7 Hills Pharma, known for its innovative integrin-targeted agonists designed to boost immunotherapies.
• - BeyondSpring Pharmaceuticals, with its first-in-class immunomodulating agent, plinabulin.
• - GE HealthCare, a pioneer in imaging agents that enhance diagnostic accuracy in cancer treatments.
• - Coherus Oncology, aiming to develop next-generation immuno-oncology therapies that help extend patient survival.

These companies are leading the charge to implement novel strategies and technologies designed to improve treatment efficiencies and patient outcomes.

Focus Areas of Discussion

During the summit, several key areas will be highlighted:

• - Biomarkers and Diagnostics: The need for reliable biomarkers and effective diagnostics plays a crucial role in personalizing cancer treatments.
• - Assay Development: Developing performant assays is essential for understanding how drugs interact within the biological systems of patients.
• - Liquid Biopsies: Innovations in liquid biopsies not only enhance cancer detection but also allow for ongoing monitoring of treatment responses, which is invaluable in the fight against cancer.

Networking Opportunities

The event also offers extensive networking opportunities for participants, fostering collaborations between biotech firms, pharmaceutical companies, and solution providers. This collaborative environment is essential for catalyzing advancements in the drug development process and accelerating the delivery of innovative treatments to patients worldwide.

Conclusion

As immuno-oncology continues to push the boundaries of cancer treatment, the Immuno-Oncology 360º Summit 2026 serves as a critical platform for sharing insights and developments among industry leaders. Participants can expect valuable discussions, networking opportunities, and firsthand insights into the future of cancer immunotherapy. For more information about participating or sponsoring, visit io360summit.com.